EARNINGS RELEASE – THIRD QUARTER OF 2012

São Paulo, November 13, 2012. RaiaDrogasil S.A. (BM&FBovespa: RADL3) announces today its results for the 3rd quarter of 2012 (3Q12). The consolidated quarterly information of RaiaDrogasil S.A. and of its wholly-owned subsidiary Raia S.A. for the period ended September 30th, 2012 were prepared in accordance with IFRS and were reviewed by our independent auditors in accordance with Brazilian and international standards of auditing. Such financial statements were prepared in Reais and all growth rates are related to the same period of 2011.

In order to allow the comparison to our 2012 consolidated financials, we are supplementally presenting non-reviewed combined quarterly information of RaiaDrogasil S.A. and of Raia S.A. for 2011. This combined quarterly information represents a summation of the reviewed unconsolidated individual financial statements of RaiaDrogasil and of Raia for the fiscal year, without the equity effects of Raia recognized into RaiaDrogasil. The combined non-reviewed quarterly information for 2011 do not reflect the pro forma adjustments that would be necessary on the assumption that the operations of Raia and Drogasil would have occurred on the first day of the period, but instead may and should be considered as representative of our future results.

As a result of the creation of RaiaDrogasil, we incurred both in 2012 and in 2011 on certain non-recurring expenses related to the transaction and to the alignment of certain accounting practices between the entities, as well as on additional depreciation and amortization related to the allocation of the transaction purchase price (PPA) to acquired tangible and intangible assets in accordance with IFRS. To facilitate a better understanding and analysis of our operating performance, we are supplementally presenting adjusted results for 2012 and 2011 excluding the effects of non-recurring expenses.

HIGHLIGHTS:

- **Drugstores: 828 stores in operation (24 new store openings and three closings)**
- **Gross Revenues: R$ 1,451.8 million, 17.8% of growth (11.2% for same-store sales)**
- **Gross Margin: 26.2% of gross revenues, a 0.7 percentage point margin increase**
- **Adjusted EBITDA: R$ 81.1 million, an increase of 18.6%**
- **Adjusted EBITDA Margin: 5.6%, in line with the previous year**
- **Adjusted Net Income: R$ 39.7 million, 2.7% of net margin**
- **Cash Generation: R$ 112.4 million**

RADL3: **R$22.00/share**

Number of Shares: **330,386,000**

Market Cap: **R$ 7,268 million**

Closing: **November 12th, 2012**

IR Contacts:

Eugênio De Zagottis
Gabriel Rozenberg
Corina Steindler

Phone: +55 11 3165-7858

E-mail: ri@raiadrogasil.com.br

Combined Summary	3Q11	4Q11	1Q12	2Q12	3Q12
(R$ thousand)					
# of Stores (end of period)	743	776	785	807	828
Store Openings	31	40	9	26	24
Store Closures	3	7	0	4	3
# of Stores (average)	733	759	781	795	819
Head Count	16,278	17,244	18,510	19,383	19,927
# of Tickets	29,315	30,143	29,790	31,193	32,360
Gross Revenues	1,232,279	1,287,973	1,286,847	1,375,186	1,451,823
Gross Profit (Adjusted)	314,639	337,867	327,176	386,922	380,484
% of Gross Revenues	25.5%	26.2%	25.4%	28.1%	26.2%
EBITDA (Adjusted)	68,433	76,167	61,362	100,246	81,144
% of Gross Revenues	5.6%	5.9%	4.8%	7.3%	5.6%
Net Income (Adjusted)	35,049	43,335	27,484	53,791	39,694
% of Gross Revenues	2.8%	3.4%	2.1%	3.9%	2.7%

RaiaDrogasil

STORE DEVELOPMENT

We ended the 3Q12 with 828 stores in operation through the opening of 24 new stores and the closing of three. We opened 18 Drogasil stores against only six Droga Raia stores in the quarter, due to the preparation of the incorporation of Raia S.A. by RaiaDrogasil S.A., which implied the opening suspension of the new Raia stores that were not fully licensed by the end of the 2Q12. These stores will be opened as RaiaDrogasil from the date of the incorporation, which is programmed for November 30th, 2012.

We have already opened a total of 59 stores and closed seven in 2012. At the end of the period, 34.3% of our stores were still undergoing maturation, and had not yet reached their full potential in terms of revenues and profitability.

Store Count



	3Q11	4Q11	1Q12	2Q12	3Q12
Opened	31	40	9	26	24
Closed	3	7	0	4	3

Age Structure of Store Portfolio
(store count, % of existing stores)



We reached in the month of June a national market share of 9.1%, an annual share increase of 0.4 percentage point. The chart below illustrates our geographic presence and the market share evolution in the states where we operate.

Geographic Presence



Market Share (September, 12)



PHARMACEUTICAL MARKET DISTRIBUTION BY STATE (LAST 12 MONTHS)

Brasil	SP	DF	GO	ES	MG	PR	RJ	MS	MT	SC	RS	BA
100.0%	28.2%	2.7%	3.3%	2.0%	10.2%	6.0%	13.2%	1.1%	1.1%	3.8%	7.4%	4.5%

IBRX IBRA IGCT ITAG IGC ICON MLCX RADL3 NOVO MERCADO BM&FBOVESPA

We gained market share in most markets where we operate. The main highlight was the significant increase achieved in the state of São Paulo, our main market, and also in Rio de Janeiro, where we recorded a 2.0 percentage point and 1.0 percentage point increase, respectively.

Another highlight was our growth in the Midwest region, with a 0.2 percentage point increase in Goiás, reversing a downward trend, and with a 0.3 percentage point expansion in Distrito Federal. This market share gain, together with the 26 new stores acquired from Drogaria Santa Marta to be opened in Goiás and with our recent entry into Mato Grosso (2Q12) and Mato Grosso do Sul (3Q12), where we recorded 2.9 and 3.0 of market share in the quarter, respectively, will allow us to consolidate our leadership in this important Brazilian region, where we will reach a total of 120 stores in the beginning of 2013.

We also strengthened our presence in Santa Catarina, a state in which we began operating in 2011 and reached 20 stores and 2.9% of market share in the quarter. Finally, we highlight our entry into the Northeast, the fastest growing region in Brazil, through the opening of six stores in Bahia, the region's main state both in economic and population terms. In the initial quarter of operations, we recorded a market share of 0.4% in the state.

GROSS REVENUES

We recorded gross revenues of R$ 1,451.8 million in the quarter, a 17.8% increase over the 3Q11. We reached 11.2% of growth for our same store sales and 7.2% for our mature stores, those with three or more years in operation. It is important to mention that we had a calendar effect in the quarter that penalized our sales by 0.9% due to the fact that this quarter had less working days than in the same period of last year.



Our mature stores grew by 8.6% for Drogasil and by 5.7% for Droga Raia, both above the CPI (IPC-A) of 5.28% recorded in the period. Adjusted by the negative calendar effect, mature store growth would have been 9.5% at Drogasil and 6.6% at Droga Raia. It is important to highlight the differences between the comp basis of the 3Q11, when Drogasil posted mature stores growth of 5.1% against 10.5% for Droga Raia.

Gross Revenues

(R$ million)



Sales Mix



We recorded a 23.1% increase in Generics, our fastest growing category in the quarter, and of 18.7% in Hygiene and Personal Care. Generics share in our sales mix increased to 11.3%, a 0.5 percentage point increase over the same period in the previous year.

Generics growth constitutes an important gross margin expansion lever, because they are significantly more profitable than branded pharmaceuticals. The main drivers of this growth have been the wave of new generics introductions and our improved execution in generics at our stores.

GROSS PROFIT

We ended the 3Q12 with an adjusted gross margin of 26.2%, a 20.9% increase and a 0.7 percentage point gross margin expansion over the 3Q11.

We recorded in the quarter an important change in tax regime, upon which RaiaDrogasil became its own substitute taxpayer in São Paulo. Therefore, instead of purchasing products with taxes previously retained by our suppliers on our behalf, we began paying our own ICMS (state taxes) when products are shipped to our stores. This allows us to convert into cash the retained ICMS on inventories (R$ 50.4 million, equivalent to 4.5 days of cash cycle) as well as to offset taxes due with tax credits outstanding (R$ 73.1 million, considering that R$ 23.5 have already been offset in the quarter).

However, this new regime generated an increase in our tax burden for all products which suppliers distribute through an interdependent distributor, which belongs to the same economic group, as part of their tax planning. In this situation, our tax burden increases by the same amount of their tax breaks achieved through that fiscal structure, which represented an overall negative effect of 0.8 percentage point in our gross margins. Notwithstanding, we still achieved a 0.7 percentage point gross margin increase over the 3Q11.

Adjusted Gross Profit
(R$ million, % of gross revenues)



* Excludes R$ 1.6 million of PPA amortization on inventories in the 1Q12 and R$ 7.1 million in 2011, and R$ 23.3 million of accounting alignment between Raia and Drogasil in 2011.

SALES EXPENSES

Sales expenses totaled R$ 261.3 million in the quarter, amounting to 18.0% of gross revenues. We experienced a 1.4 percentage point increase when compared to the same period in 2011.

Sales Expenses
(R$ million)



Sales Expenses
(% of gross revenues)



The increase in staff deployment and the annual salary readjustment penalized our sales expenses in existing stores at the end of the quarter by 0.8 percentage point. Furthermore, we also experienced a 0.2 percentage point increase in our commercial leases due to the steep appraisal of the Brazilian property market.

The opening of two new distribution centers over the last twelve months brought additional expenses of R$ 2.6 million in the 3Q12, equivalent to 0.2 percentage point of our gross revenues in the quarter. We are opening a new distribution center in Ribeirão Preto, in the countryside of São Paulo, which will allow us to support our expansion. In addition to this DC, which is still in the pre operational stage, we also opened our first distribution center in Rio de Janeiro in the 1Q12, with 8,400 square meters.

Our accelerated store development has impaired our capacity to absorb sales expenses. Pre operational expenses totaled R$ 6.0 million in the 3Q12, a R$ 3.8 million increase, equivalent to 0.3 percentage point over the previous year.

On a quarterly basis, we registered a total increase in our sales expenses of 0.4 percentage point over the 2Q12, which is fully explained by the salary readjustment of 6.5% granted in July, exceeding the annual CPI by 1.6%.

GENERAL AND ADMINISTRATIVE EXPENSES

General and Administrative expenses amounted to R$ 38.1 million in the quarter, equivalent to 2.6% of our gross revenues, which represented a 0.8 percentage point decrease when compared to the same period in 2011.





* Excludes R$ 3.5 million of non-recurring expenses recorded in the 3Q12 (R$ 2.7 million in consulting and severance expenses, R$ 0.5 million in store closures and R$ 0.3 in the incorporation of Raia into RaiaDrogasil), R$ 2.7 million in the 2Q12 (consulting and store closures), R$ 6.6 million in the 1Q12 (consulting and severance expenses) and R$ 35.3 million recorded in 2011 (general transaction expenses, including banking fees, consulting expenses and alignment of accounting practices).

We have enhanced the absorption of our corporate structure since the 3Q11 due to the unification of our top and middle management teams and to a limitation in new admissions. We also recorded in the quarter R$ 4.9 million related to a reversion in our variable compensation allowance.

We emphasize that our reported expenses do not reflect non-recurring items related to the merger, such as consulting and advisory fees and severance expenses, which have totaled R$ 3.5 million in the quarter.

EBITDA

We reached R$ 81.1 million of adjusted EBITDA in the quarter, an 18.6% increase over the 3Q11. Our EBITDA margin remained at the same level, and represented 5.6% of gross revenues.

It is important to highlight that the stores that have been opened throughout the year or that were at pre-operational stage by the end of the 3Q12 penalized our EBITDA by R$ 8.4 million in the quarter. Therefore, the 776 stores that we had in operation at the end of 2011, produced an adjusted EBITDA of R$ 89.5 million, equivalent to an EBITDA margin of 6.2% over gross revenues of R$ 1.45 billion in the quarter.



* Excludes R$ 3.5 million of non-recurring expenses in the 3Q12 (R$ 2.7 million in consulting and severance expenses, R$ 0.5 in store closures and R$ 0.3 million in the merger of Raia by RaiaDrogasil), R$ 2.7 million in the 2Q12, R$ 8.2 million in the 1Q12 and R$ 57.9 million in 2011.

EBITDA Reconciliation	3Q11	3Q12	9M11	9M12
(R$ thousand)				
Net Income	**31.8**	**34.7**	**94.8**	**103.4**
Net Financial Expenses (Revenues)	(6.5)	1.6	(19.9)	1.1
Income Tax	17.2	9.5	46.0	32.6
Depreciation and Amortization	23.3	31.9	67.3	91.2
EBITDA	**65.8**	**77.7**	**188.2**	**228.3**
Consulting Expenses	0.8	2.7	0.8	11.1
Store Closures		0.5		1.4
Raia Merger		0.3		0.3
PPA Amortization over Inventories				1.6
Trade Allowance Alignment	1.8		6.4	
Adjustments	**2.6**	**3.5**	**7.2**	**14.4**
Adjusted EBITDA	**68.4**	**81.1**	**195.4**	**242.8**
% of Gross Revenues	5.6%	5.6%	5.7%	5.9%

* The 3Q11 EBITDA was impacted by R$ 2.6 million of non-recurring expenses, which corresponded to the quarter's accrual (R$ 1.8 million) of the R$ 11.0 million charge for the alignment in the criteria for trade allowance recognition and consulting and severance expenses (R$ 0.8 million), which were reported in the 4Q11.

FINANCIAL EXPENSES, DEPRECIATION AND NET INCOME

Our net financial expenses totaled R$ 1.6 million in the quarter, equivalent to 0.1% of our gross revenues when compared to net financial revenues of R$ 8.8 million in 3Q11. This reduction stemmed from the cash consumption incurred in the last 12 months, which reduced net cash and financial income.

Depreciation totaled R$ 27.8 million, or 1.9% of gross revenues, and remained constant due to the maintenance of a strong investment pace.

We recorded an adjusted net income of R$ 39.7 million, a 13.4% increase over 2011, and net margin of 2.7%.







* Excludes R$ 5.0 million of non-recurring expenses incurred in the 3Q12 (R$ 3.5 million in general and administrative expenses and R$ 1.5 million of PPA amortization, including income taxes), R$ 4.5 million in the 2Q12, R$ 8.2 million in the 1Q12 and R$ 45.7 million in 2011.

When considering the non-recurring expenses related to the transaction, net income totaled R$ 34.7 million, an increase of 9.1% over the 3Q11 and a net margin of 2.4% of gross revenues.

CASH CYCLE

We invested 3.4 days of cash cycle when compared to the 3Q11, as shown below:

We reduced our cash cycle by 15.1 days when compared to previous quarter, and brought it in line with the same period in 2011. This significant cash cycle reduction reflects a realignment of our inventory levels across our distribution centers after a period of transitory pressures due to the rapid increase in the DC count.



We recorded in the quarter an important change in tax regime, upon which RaiaDrogasil became its own substitute taxpayer in São Paulo. Therefore, instead of purchasing products with taxes previously retained by our suppliers on our behalf, we began paying our own ICMS (state taxes) when products are shipped to our stores.

This allows us to convert into cash the retained ICMS on inventories (R$ 50.4 million, equivalent to 4.5 days of cash cycle) as well as to offset taxes due with retained tax credits (R$ 73.1 million). It is important to highlight that in the 3Q12 we were already able to convert R$ 23.5 million of outstanding tax credits.

As a result of this change, the ICMS on inventories (R$ 50.4 million) was transferred to the taxes receivables line, and shall be converted into cash over the next quarters. This reduction in inventories contributed to a decrease in our cash cycle of 4.5 days.

CASH FLOW

We experienced in the third quarter of 2012 a cash generation of R$ 112.4 million.

We generated R$ 71.6 million in resources from operations, corresponding to 4.9% of our gross sales, an increase of 12.4% over 2011, and employed R$ 97.4 million in working capital, when compared to a reduction in working capital of R$ 10.6 million in the 3Q11. Of this amount, R$ 23.5 million was of the use of remaining tax credits.

We also invested R$ 56.6 million in the quarter: R$ 30.8 million in store development, R$ 7.6 million in the maintenance of existing stores, and R$ 18.2 million in the upgrade of our infrastructure.

We accrued R$ 14.5 million in interest on equity in the quarter.

Cash Flow *(R$ million)*	**3Q12**	**3Q11**	**9M12**	**9M11**
EBT	**44.2**	**49.1**	**136.0**	**140.8**
(-) Income Tax	(12.1)	(12.6)	(18.2)	(25.9)
(+) Depreciation	31.9	23.3	91.2	67.3
(-) Other Adjustments	7.5	3.9	19.7	13.6
Resources from Operations	**71.6**	**63.7**	**228.6**	**195.8**
Cash Cycle*	103.1	1.4	(158.8)	(305.8)
ICMS Recovery	23.5	-	43.2	-
Others	(29.2)	9.2	(51.7)	21.3
Operations	**169.0**	**74.3**	**61.2**	**(88.8)**
Investments	**(56.6)**	**(43.0)**	**(144.9)**	**(97.7)**
Total Cash Flow	**112.4**	**31.3**	**(83.7)**	**(186.5)**

* Cash cycle includes variation in accounts receivables, inventories and suppliers

** Does not include financing cash flow

CAPITAL MARKETS

Considering the stock price of R$ 22.00 on November 12th, 2012, we recorded a cumulative return of 69.6% in 2012. Our appreciation exceeded IBOVESPA's by 69.1 percentage points, reflecting our performance, the trust bestowed on us by our investors and the increasing understanding that the pharmaceutical retail is a defensive sector that remains relatively immune from adverse macroeconomic conditions.

In the 3Q12, our average daily trading volume was of R$ 22.1 million, when compared to the average liquidity of R$ 18.9 million that we recorded since the beginning of 2012.

The chart below highlights the increase in our stock price since the IPO of Drogasil in June 2007. We achieved a cumulative increase of 292.9% when compared to 4.9% registered by the IBOVESPA over the same period, a compounded annual return of 29.0% in the period.

For those who invested at the Raia IPO in December of 2010, the cumulative return in the period amounted to 110.0% when compared to a decrease of 16.1% recorded by the IBOVESPA, a compounded annual return of 47.6% in the period.

Share Evolution

(Base 100)



Adjusted Income Statement	3Q11	3Q12	9M11	9M12
(R$ thousand)				
Gross Revenues	**1,232,279**	**1,451,823**	**3,442,061**	**4,113,856**
Taxes, Discounts and Returns	(47,645)	(55,612)	(132,961)	(157,139)
Net Revenues	**1,184,635**	**1,396,211**	**3,309,100**	**3,956,717**
Cost of Goods Sold	(869,995)	(1,015,727)	(2,434,114)	(2,862,136)
Gross Profit	**314,639**	**380,484**	**874,985**	**1,094,581**
Operational (Expenses) Revenues				
Sales	(204,500)	(261,255)	(567,545)	(726,624)
General and Administrative	(41,707)	(38,085)	(112,060)	(125,205)
Other Operational Expenses, Net				
Operational Expenses	**(246,207)**	**(299,340)**	**(679,605)**	**(851,829)**
EBITDA	**68,433**	**81,144**	**195,380**	**242,752**
Depreciation and Amortization	(23,310)	(27,831)	(67,257)	(79,054)
Operational Earnings before Financial Results	**45,123**	**53,313**	**128,123**	**163,698**
Financial Expenses	(4,564)	(4,650)	(16,711)	(14,077)
Financial Revenues	13,375	3,086	40,848	12,931
Financial Expenses/Revenues	**8,811**	**(1,564)**	**24,137**	**(1,146)**
Earnings before Income Tax and Social Charges	**53,934**	**51,749**	**152,260**	**162,552**
Income Tax and Social Charges	**(18,885)**	**(12,055)**	**(44,237)**	**(41,581)**
Net Income	**35,049**	**39,694**	**108,023**	**120,971**

Income Statement *(R$ thousand)*	3Q11	3Q12	9M11	9M12
Gross Revenues	**1,232,279**	**1,451,823**	**3,442,061**	**4,113,856**
Taxes, Discounts and Returns	(47,645)	(55,612)	(132,961)	(157,139)
Net Revenues	**1,184,635**	**1,396,211**	**3,309,100**	**3,956,717**
Cost of Goods Sold	(871,826)	(1,015,727)	(2,440,561)	(2,863,745)
Gross Profit	**312,808**	**380,484**	**868,539**	**1,092,972**
Operational (Expenses) Revenues				
Sales	(204,500)	(261,255)	(567,545)	(726,625)
General and Administrative	(41,707)	(38,085)	(112,059)	(125,205)
Other Operational Expenses, Net	(755)	(3,486)	(755)	(12,828)
Operational Expenses	**(246,961)**	**(302,826)**	**(680,359)**	**(864,659)**
EBITDA	**65,847**	**77,658**	**188,181**	**228,314**
Depreciation and Amortization	**(23,310)**	**(31,868)**	**(67,257)**	**(91,165)**
Operational Earnings before Financial Results	**42,537**	**45,790**	**120,924**	**137,149**
Financial Expenses	(4,564)	(4,650)	(16,711)	(14,077)
Financial Revenues	11,103	3,086	36,615	12,931
Financial Expenses/Revenues	**6,539**	**(1,564)**	**19,903**	**(1,146)**
Earnings before Income Tax and Social Charges	**49,076**	**44,226**	**140,826**	**136,003**
Income Tax and Social Charges	(17,230)	(9,497)	(45,998)	(32,555)
Net Income	**31,846**	**34,729**	**94,828**	**103,448**

Assets	3Q11	3Q12
(R$ thousand)		
Current Assets		
Cash and Cash Equivalents	383,794	218,404
Financial Assets Held to Maturity	16,444	
Accounts Receivable	260,816	332,875
Inventories	726,519	829,405
Taxes Receivable	87,188	62,110
Other Accounts Receivable	74,658	103,853
Following Fiscal Year Expenses	7,965	11,472
	1,557,384	1,558,119
Non-Current Assets		
Deposit in Court	7,499	10,349
Taxes Receivable	30,884	66,609
Income Tax and Social Charges deferred	37,106	
Other Credits	754	1,168
Investments		
Property, Plant and Equipment	351,088	422,083
Intangible	92,357	1,127,769
Goodwill		
	519,688	1,627,978
ASSETS	2,077,071	3,186,097

Liabilities and Shareholder's Equity	3Q11	3Q12
(R$ thousand)		
Current		
Suppliers	431,566	466,636
Loans and Financing	51,806	61,011
Salaries and Social Charges Payable	102,426	120,587
Taxes Payable	36,337	40,998
Dividend and Interest on Equity	14,701	35,051
Provision for Lawsuits	971	3,131
Other Accounts Payable	56,472	52,608
	694,280	780,022
Non-Current Assets		
Loans and Financing	105,972	87,962
Provision for Lawsuits	5,907	4,123
Income Tax and Social Charges deferred	4,206	51,488
Other Accounts Payable	9,441	7,487
	125,526	151,060
Shareholder's Equity		
Common Stock	840,217	908,639
Capital Reserves	138,638	1,039,935
Revaluation Reserve	13,376	13,174
Income Reserves	267,338	229,536
Accrued Income		63,731
Treasury Stock	(2,304)	
Additional Dividend Proposed		
	1,257,265	2,255,015
LIABILITIES AND SHAREHOLDERS' EQUITY	2,077,071	3,186,097

	3Q11	3Q12	9M11	9M12
Cash Flow				
Earnings before Income Tax and Social Charges	**49,076**	**44,226**	**140,826**	**136,003**
Adjustments				
Depreciations and Amortization	23,310	31,868	67,256	91,165
Stock Option Plan	384		650	
P,P&E and Intangible Assets residual value	(621)	696	(143)	1,691
Provisioned Lawsuits	554	555	171	1,039
Provisioned Inventories Loss	1,714	1,552	2,578	3,227
Allowance for Doubtful Accounts	(1,667)	929	(1,374)	1,901
Interest Expenses	3,572	3,816	11,693	11,850
	76,322	**83,642**	**221,657**	**246,877**
Assets and Liabilities variation				
Financial Investments	(183)		(1,125)	
Accounts Receivable	(4,102)	(23,524)	(63,421)	(71,447)
Inventories	(121)	69,804	(126,227)	(17,658)
Other Short Term Assets	(7,972)	32,758	(27,694)	32,009
Long Term Assets	1,020	(41,621)	(764)	(34,418)
Suppliers	5,623	56,805	(116,163)	(69,731)
Salaries and Social Charges	18,222	15,115	32,325	28,128
Taxes Payable	(4,866)	(9,354)	(2,879)	(10,027)
Other Liabilities	2,045	(2,632)	17,079	(26,095)
Rent Payable	952	63	3,235	1,851
Cash from Operations	**86,940**	**181,056**	**(63,977)**	**79,489**
Income Tax and Social Charges Paid	(12,610)	(12,066)	(25,901)	(18,244)
Net Cash from (invested) Operational Activities	**74,330**	**168,990**	**(89,878)**	**61,245**
Investment Activities Cash Flow				
P,P&E and Intangible Acquisitions	(44,030)	(56,783)	(98,723)	(146,276)
P,P&E Sale Payments	1,007	215	1,019	1,368
Restricted Investments				
Net Cash from Investment Activities	**(43,023)**	**(56,568)**	**(97,704)**	**(144,908)**
Financing Activities Cash Flow				
Funding		20,000	47,132	46,562
Payments	(8,748)	(36,301)	(34,553)	(61,951)
Interest Paid	(2,603)	(2,567)	(9,912)	(9,797)
Common Stock increase, net from Share Issuance expenditures			22,290	
Exercise of Stock Option Plan Payment			265	
Treasury Stock Sale Payment				
Interest on Equity and Dividends Paid	(169)	(77)	(15,567)	(12,718)
Cash and Cash Equivalents in the beggining of the period	**(11,520)**	**(18,945)**	**9,655**	**(37,904)**
Cash and Cash Equivalents net increase	**19,787**	**93,477**	**(177,927)**	**(121,567)**
Cash and Cash Equivalents in the beggining of the period	**364,007**	**124,927**	**561,721**	**339,971**
Cash and Cash Equivalents in the end of the period	**383,794**	**218,404**	**383,794**	**218,404**

RaiaDrogasil

3Q12 Results Schedule

RaiaDrogasil will disclose its results for the 3Q12 on November 13th, 2012, after BM&FBovespa's trading hours.

Conference Calls – November 14th, 2012

Portuguese
at 10:00 am (Brasília) / 07:00 am (US ET)

Dial in access:
+55 (11) 3127-4971
Conference ID: RaiaDrogasil

Replay (available 'til 11/21/12):
+55 (11) 3127-4999
Replay ID: 11601287

English
at 12:00 pm (Brasília) / 09:00 am (US ET)

Dial in access:
+1 (412) 317-6776
Conference ID: RaiaDrogasil

Replay (available 'til 11/21/12):
+1 (412) 317-0088
Replay ID: 10019332

Live broadcast through the internet at: www.raiadrogasil.com.br

Quiet Period: According to best Corporate Governance Practices, we will be in quiet period from October 30th, 2012 to November 14th, 2012, after the Conference call.

For more information, please contact our Investor Relations department.

E-mail: ri@raiadrogasil.com.br